← Filings of COO

Tables in the 10-Q of COOPER COMPANIES, INC.

36 tables with numbers, filed Jun 5, 2026. Each one downloads as a CSV for Excel or Google Sheets, with the filing's address in the last row. Only the layout is tidied (a "$" or ")" in a cell of its own is joined to its number); no value is changed. Open the filing on sec.gov ↗

		Page No.
PART I.	FINANCIAL INFORMATION
Item 1.	Unaudited Financial Statements
	Consolidated Condensed Statements of Income (Loss) and Comprehensive Income (Loss)	3
	Consolidated Condensed Balance Sheets	4
	Consolidated Condensed Statements of Stockholders' Equity	5
	Consolidated Condensed Statements of Cash Flows	7
	Notes to Consolidated Condensed Financial Statements	8

	Three Months	Six Months
	2026	2025		2026	2025
Net sales	$1,081.5		$1,002.3		$2,105.6	$1,967.0
Cost of sales	346.1		323.2		675.0	627.7
Gross profit	735.4		679.1		1,430.6	1,339.3
Selling, general and administrative expense	676.2		399.0		1,066.4	786.9
Research and development expense	42.5		45.5		86.8	86.2
Amortization of intangibles	47.7		49.8		95.6	99.4

	April 30, 2026	October 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$138.8		$110.6
Trade accounts receivable, net of allowance for credit losses of $69.1 at April 30, 2026, and $51.9 at October 31, 2025	809.2		829.0
Inventories (Note 2)	896.4		846.0
Prepaid expense and other current assets	455.4		320.8
Total current assets	2,299.8		2,106.4

	Common Shares	Treasury Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Loss	Retained Earnings		Treasury Stock	Noncontrolling Interests	Total Stockholders' Equity
	Shares	Amount	Shares		Amount
Balance at October 31, 2024	199.6		$19.9			17.6		$1.8		$1,921.0		$(421.7)	$7,268.4	$(706.0)	$0.2	$8,083.6
Net income (loss)	—		—			—		—		—		—	104.3	—	—	104.3
Other comprehensive income (loss), net of tax	—		—			—		—		—		(68.7)	—	—	—	(68.7)
Issuance of common stock for stock plans, net and employee stock purchase plan	0.3		—			—		—		(11.0)		—	—	1.0	—	(10.0)
Share-based compensation expense	—		—			—		—		18.3		—	—	—	—	18.3
Balance at January 31, 2025	199.9		$19.9			17.6		$1.8		$1,928.3		$(490.4)	$7,372.7	$(705.0)	$0.2	$8,127.5

	2026	2025
Cash flows from operating activities:
Net income	$52.9		$192.0
Depreciation and amortization	190.9		183.6
Settlement of contingent consideration	(0.5)		—
Net changes in operating capital	55.5		(241.2)
Deferred income taxes	87.1		78.3
Other non-cash items	57.8		74.1

(In millions)	April 30, 2026	October 31, 2025
Raw materials	$180.5		$193.1
Work-in-process	20.9		19.9
Finished goods	695.0		633.0
Total inventories	$896.4		$846.0

Fiscal Years:	(In millions)
Remainder of 2026	$93.7
2027	174.8
2028	170.2
2029	166.0
2030	161.6
Thereafter	726.9
Total remaining amortization for intangible assets with definite lives	$1,493.2

Periods Ended April 30,	Three Months	Six Months
(In millions, except per share amounts)	2026	2025		2026	2025
Net income (loss)	$(77.9)		$87.7		$52.9	$192.0
Basic:
Weighted-average common shares	195.0		199.9		195.4	199.8
Basic earnings (loss) per share	$(0.40)		$0.44		$0.27	$0.96
Diluted:
Weighted-average common shares	195.0		199.9		195.4	199.8

(In millions)	Foreign Currency Translation Adjustment	Minimum Pension Liability		Derivative Instruments	Total
Balance at October 31, 2024	$(461.7)		$(4.9)		$44.9	$(421.7)
Gross change in value	51.0		—		(28.5)	22.5
Tax effect	—		—		6.9	6.9
Balance at April 30, 2025	$(410.7)		$(4.9)		$23.3	$(392.3)
Balance at October 31, 2025	$(426.2)		$1.7		$18.0	$(406.5)
Gross change in value	46.9		—		(4.8)	42.1
Tax effect	—		—		1.2	1.2

(In millions)	CooperVision	CooperSurgical		Corporate (1)	Consolidated
Three Months Ended April 30, 2026
Net sales	$723.5		$358.0		$—	$1,081.5
Cost of sales	229.4		116.7		—	346.1
Selling, general and administrative expense	252.2		402.4		21.6	676.2
Research and development expense	22.1		20.4		—	42.5
Amortization expense	4.2		43.5		—	47.7
Operating income (loss)	$215.6		$(225.0)		$(21.6)	$(31.0)

	April 30, 2026	October 31, 2025
(In millions)	Gross Carrying Amount	Accumulated Amortization		Gross Carrying Amount	Accumulated Amortization
Intangible assets with definite lives:
Customer relationships	$1,142.2		$501.8		$1,137.6	$469.3
Composite intangible assets (1)	1,101.7		607.6		1,101.7	570.7
Technology	684.5		435.9		683.4	415.3
Trademarks	203.0		109.1		202.5	102.3
License and distribution rights and other	44.6		28.4		44.5	26.9

(In millions)	April 30, 2026	October 31, 2025
Term loans	$550.0		$—
Other	48.2		47.1
Short-term debt, excluding financing leases	598.2		47.1
Financing lease liabilities	0.7		0.7
Short-term debt	$598.9		$47.8
Revolving credit	$911.7		$956.3
Term loans	950.0		1,500.0

Periods Ended April 30,	Three Months	Six Months
(In thousands, except exercise prices)	2026	2025		2026	2025
Stock option shares excluded	3,480		1,506		1,481	1,111
Exercise prices	$43.83 - $101.54	$82.46 - $101.54		$78.51 - $101.54	$82.46 - $101.54
Restricted stock units excluded	1,961		586		348	563

Periods Ended April 30,	Three Months	Six Months
(In millions)	2026	2025		2026	2025
Net sales to unaffiliated customers by country of domicile:
United States	$547.8		$515.2		$1,061.7	$1,011.6
Europe	341.6		291.9		668.0	579.4
Rest of world	192.1		195.2		375.9	376.0
Total	$1,081.5		$1,002.3		$2,105.6	$1,967.0

Three Months Ended April 30,				2026 vs 2025% Change
($ in millions)	2026	2025
Toric and multifocal	$364.9		$328.4		11%
Sphere, other	358.6		341.2		5%
	$723.5		$669.6		8%

Six Months Ended April 30,				2026 vs 2025% Change
($ in millions)	2026	2025
Toric and multifocal	$716.1		$647.8		11%
Sphere, other	702.5		667.9		5%
	$1,418.6		$1,315.7		8%

($ in millions)	Facility Limit	Outstanding Borrowings		Outstanding Letters of Credit	Total Amount Available	Maturity Date
Revolving Credit:
2024 Revolving Credit	$2,300.0		$911.7		$5.3		$1,383.0		May 1, 2029
Term loan:
2021 Term Loan	550.0		550.0		n/a	—		December 17, 2026
2021 Term Loan	950.0		950.0		n/a	—		February 3, 2031
Total	$3,800.0		$2,411.7		$5.3		$1,383.0

Period	Total number of shares purchased (in thousands)	Average price paid per share		Total number of shares purchased as part of publicly announced plan (in thousands)	Approximate dollarvalue of shares that may yet be purchased under the plan (in millions)
February 1, 2026 to February 28, 2026	—		$—		—	$873.9
March 1, 2026 to March 31, 2026	173.6		75.84		173.6	860.8
April 1, 2026 to April 30, 2026	—		—		—	860.8
Total	173.6		$75.84		173.6	$860.8

		Incorporated by Reference	Filed Herewith
ExhibitNumber	Description of Document	Form	Exhibit	Filing Date/ Period End Date
31.1	Certification of the Chief Executive Officer, pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934				X
31.2	Certification of the Chief Financial Officer, pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934				X
32.1*	Certification of the Chief Executive Officer, pursuant to 18 U.S.C. Section 1350				X
32.2*	Certification of the Chief Financial Officer, pursuant to 18 U.S.C. Section 1350				X
101.1	The following materials from the Company's Quarterly Report on Form 10-Q for the three and six months periods ended April 30, 2026 formatted in Inline XBRL (Extensible Business Reporting Language): (i) Consolidated Condensed Statements of Income (Loss) and Comprehensive Income (Loss), (ii) Consolidated Condensed Balance Sheets, (iii) Consolidated Condensed Statements of Stockholders' Equity, (iv) Consolidated Condensed Statements of Cash Flows and (v) related Notes to Consolidated Condensed Financial Statements.
104.1	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Tables in the 10-Q of COOPER COMPANIES, INC.

Table 1 after “INDEX”

Table 2 after “(Unaudited)”

Table 3 after “(Unaudited)”

Table 4 after “(In millions, unaudited)”

Table 5 after “(In millions, unaudited)”

Table 6 after “(In millions, unaudited)”

Table 7 after “Inventories”

Table 8 after “Intangible assets consisted of the following:”

Table 9 after “As of April 30, 2026, the estimate of future amortization expenses for intangible assets with definite lives is as follows:”

Table 10 after “The Company had outstanding debt as follows:”

Table 11 after “Note 6. Earnings (Loss) Per Share”

Table 12 after “The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted e”

Table 13 after “The compensation expense and related income tax benefit recognized in our Consolidated Condensed Statements of Income (Loss) and Comprehensi”

Table 14 after “Analysis of Changes in Accumulated Other Comprehensive Loss:”

Table 15 after “Segment information:”

Table 16 after “(Unaudited)”

Table 17 after “(Unaudited)”

Table 18 after “Geographic information:”

Table 19 after “Geographic information:”

Table 20 after “The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Conden”

Table 21 after “The following table details the changes in the cumulative pre-tax impact of the gain on derivatives designated for hedge accounting:”

Table 22 after “CooperVision Net Sales by Category”

Table 23 after “and Results of Operations”

Table 24 after “CooperVision competes in the worldwide soft contact lens market and services in three primary regions: the Americas, EMEA (Europe, Middle Ea”

Table 25 after “CooperSurgical Net Sales by Category”

Table 26 after “and Results of Operations”

Table 27 after “Selling, General and Administrative (SGA) Expenses”

Table 28 after “Research and Development (R&D) Expenses”

Table 29 after “Amortization Expense”

Table 30 after “Operating Income (Loss)”

Table 31 after “Interest Expense”

Table 32 after “Other (Income) Expense, Net”

Table 33 after “Cash Flow”

Table 34 after “The following is a summary of the maximum commitments and the net amounts available to us under different credit facilities as of April 30, ”

Table 35 after “The following table provides information about the shares repurchased by the Company for the three months ended April 30, 2026:”

Table 36 after “Item 6. Exhibits”